Table 2.

Published histone deacetylase inhibitors clinical trials January 2007–June 2008^a

HDACi	Combination drug(s)	Phase	Indication	References
Vorinostat	None	I	Advanced multiple myeloma	[61]
	None	I	Advanced leukemias and MDS	[62]
	None	I	GI cancer (Japanese patients)	[63]
	None	I	Children with refractory solid tumors	[64]
	None	I	Solid tumors (Japanese patients)	[65]
	None	I	NHL (Japanese patients)	[66]
	None	I	Malignant gliomas	[67]
	None	II	Refractory CTCL	[13••]
	None	II	Persistent or recurrent epithelial ovarian or primary peritoneal carcinoma	[68]
	None	II	Relapsed or refractory breast, colorectal, or NSCLC	[69]
	None	II	Recurrent and/or metastatic head and neck cancer	[70]
	None	II	Recurrent/metastatic TCC failing first line platinum-based therapy	[71]
	None	II	Relapsed NSCLC	[72]
	None	II	Recurrent GBM	[73]
	None	II	HRPC	[74]
	None	II	Relapsed or refractory indolent NHL	[75]
	None	II	Relapsed DLBCL	[76]
	None	II	Metastatic breast cancer	[77]
	None	IIb	Persistent, progressive, or treatment refractory CTCL	[12••]
	Carboplatin and paclitaxel	I	Advanced solid malignancies	[78]
	13cRA	I	Children with refractory neuroblastomas, medulloblastomas, PNETs, and atypical teratoid rhabdoid tumor	[79]
	Bortezomib	I	Relapsed/refractory multiple myeloma	[80]
	Bortezomib	I	Refractory solid tumors	[81]
	Bevacizumab	I	Kidney cancer	[82]
	Capecitabine	I	Advanced solid tumors	[83]
	Bexarotene	I	Advanced CTCL	[84]
	Gemcitabine and cisplatin/carboplatin	I	Advanced NSCLC	[85]
	Doxorubicin	I	Advanced solid tumors	[86]
	Idarubicin	I	Advanced acute leukemia	[87]
	Pemetrexed and cisplatin	I	Advanced cancer	[88]
	Azacitidine	I/II	MDS, AML	[89]
	Tamoxifen	II	Advanced breast cancer having failed prior aromatase inhibitor therapy	[90]
PCI-24781	None	I	Refractory advanced solid tumors	[91]
R306465	None	I	Advanced tumors	[92]
LBH-589	None	I	Advanced solid tumors or NHL	[93]
	None	I	Advanced solid tumors or lymphoma	[94]
	W/wo docetaxel and prednisone	I	Castration-resistant prostate cancer	[95]
SNDX-275	None	I	Refractory and relapsed acute leukemias	[56]
	None	I	Refractory solid tumors and lymphoid malignancies	[57]
	Azacitidine	I	Advanced NSCLC	[96]
MGCD0103	None	I	Advanced leukemia, MDS	[97]
	None	I	Advanced solid tumors	[59]
	None	II	Relapsed or refractory NHL	[98]
	None	II	Relapsed or refractory NHL	[99]
	Gemcitabine	I/II	Refractory solid tumors	[100]
	Azacitidine	I/II	High-risk MDS or AML	[101]
Belinostat	None	I	Advanced solid tumors	[60]
	None	I/II	Unresectable hepatocellular carcinoma	[102]
	None	II	Metastatic or recurrent platinum-resistant (<6 months) EOC and LMP ovarian tumors	[103]
	Azacitidine	I	Advanced myeloid neoplasms	[104]
	Carboplatin and paclitaxel (BelCaP)	II	Relapsed EOC	[105]
Romidepsin	None	I	Thyroid and other advanced cancers	[106]
	None	II	CTCL, PTCL	[107]
	None	II	Metastatic HRPC	[108]
	None	II	Lung cancer	[109]
	Gemcitabine	I	Pancreatic and other advanced solid tumors	[110]
ITF2357	None	II	Relapsed/refractory Hodgkin’s lymphoma	[111]
VPA	None	I	Refractory advanced cancer	[112]
	Epirubicin	I	Advanced solid tumors	[113•]
	Decitabine	I	AML	[114]
	Decitabine	I	NSCLC	[115]
	Azacytidine	I	Advanced solid cancers	[116]
	FEC100	I/II	Locally advanced/metastatic breast cancer.	[117]
	Azacitidine, ATRA	I/II	AML, MDS	[118•]
	Hydralazine	II	Refractory solid tumors	[119]

AML, acute myeloid leukemia; ATRA, all-trans retinoic acid; CTCL, cutaneous T-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; EOC, epithelial ovarian cancer; GBM, glioblastoma multiforme; GI, gastrointestinal; HDACi, histone deacetylase inhibitors; HRPC, hormone refractory prostate cancer; LMP, low malignant potential; MDS, myelodysplastic syndrome; NHL, non-Hodgkin’s lymphoma; NSCLC, nonsmall cell lung cancer; PNETs, primitive neuroectodermal tumors; PTCL, peripheral T-cell lymphoma; TCC, transitional cell urothelial cancer; VPA, valproic acid.

^aSummary of active HDACi clinical trials. References are to full-length papers or to abstracts from the 2007 and 2008 annual meetings of the American Society of Clinical Oncology.